Pharminent

CHMP recommends Revolution Medicines’ Rasonque for metastatic pancreatic cancer

EMA’s human medicines committee recommended granting a marketing authorization in the European Union for Rasonque (daraxonrasib), an oral treatment for adults with metastatic pancreatic cancer, from Revolution Medicines Netherlands B.V.

CHMP recommends six new medicines at October 2026 meeting

At its October 12-15, 2026 meeting, EMA’s CHMP recommended six medicines for approval, including Foundayo (orforglipron) from Eli Lilly Nederland B.V., Rasonque (daraxonrasib) from Revolution Medicines Netherlands B.V., and Yuviwel.

FDA approves Roche’s Enspryng for thyroid eye disease

Roche has won US approval for Enspryng in a second indication, thyroid eye disease.

Verastem reports early data for KRAS G12D inhibitor in pancreatic cancer

Verastem Oncology reported encouraging early results for its KRAS G12D inhibitor, which is being studied in more than 200 patients with advanced solid tumors including metastatic pancreatic ductal adenocarcinoma.

AstraZeneca and insitro sign cardiometabolic AI deal worth up to $1.5B

AstraZeneca and insitro have formed an AI-powered drug discovery partnership in cardiometabolic disease worth up to $1.5 billion, with a focus that includes MASH.

Armed Cell Therapeutics takes over Lakefront’s divested cell therapies

Armed Cell Therapeutics, a Belgian startup chaired by former Galapagos CEO Paul Stoffels, has assumed control of the cell therapy programs divested by the company now known as Lakefront Biotherapeutics in a strategic overhaul.

City Therapeutics prices $200M IPO for RNAi pipeline

RNAi drugmaker City Therapeutics priced a $200 million IPO, with proceeds supporting three medicines in or nearing clinical testing and earlier research into RNAi treatments that reach tissues outside the liver.

Iambic Therapeutics raises $150M in IPO for AI-driven cancer pipeline

AI-enabled biotech Iambic Therapeutics raised $150 million in its IPO and will apply the proceeds toward clinical development of its internally discovered, wholly owned cancer drugs. The company also has R&D alliances with companies including Bayer and AbbVie.

Estuary launches with $93M Series A for ADPKD genetic medicines

Biogen-backed Estuary raised a $93 million Series A led by RA Capital to fund development of two genetic medicines for the inherited kidney disorder ADPKD.

Acta Pharmaceuticals raises $24M seed for Alzheimer’s pipeline

Acta Pharmaceuticals secured $24 million in seed funding to advance a pipeline focused on early intervention and prevention of Alzheimer’s disease, including clinical progression of lead candidate GSM-779690T.

Sterling doubles ADC manufacturing capacity at Deeside, Wales site

Sterling Pharma Solutions completed a multi-million-pound expansion of its bioconjugation facility in Deeside, Wales, doubling manufacturing capacity and increasing batch scale to 500 liters. The expansion adds a GMP manufacturing suite with a 500-liter reactor and a 1,400-square-foot Grade C cleanroom.